Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015, 159(1):001-011 | DOI: 10.5507/bp.2014.049

The role of adhesion molecules in acute myeloid leukemia and (hemato)oncology: A systematic review

Tomas Kupsaa,b, Jan M. Horaceka,b, Ladislav Jebavya,b
a Department of Internal Medicine, University of Defence, Faculty of Military Health Sciences in Hradec Kralove, Czech Republic
b 4thDepartment of Internal Medicine - Hematology, Faculty of Medicine in Hradec Kralove, Charles University in Prague and University Hospital Hradec Kralove

Background: The treatment of malignancies like acute myeloid leukemia (AML) is often complicated by the heterogeneity of the disease and the mechanisms of the disease progression. This heterogeneity is often not reflected in standard treatment approaches which provide predictable outcomes in the majority of patients but fail in individual cases even with high-dose multi-agent chemotherapy regimens and allogeneic stem cell transplantation. Further, the unselective effect of chemotherapy causes high treatment-related toxicity and accelerates the risk of infection during prolonged pancytopenia, preventing further dose escalation. Despite rapid progress in therapeutic strategies, the fatality of high-grade malignancies remains enormous.

Objectives: Adhesive interactions trigger signal transduction pathway activation and this prevents the apoptosis of both normal and malignant cells. A correlation between expression of defined adhesion molecules and patient outcome has been found for several malignant diseases including AML. We aim to describe how disruption of these signalling pathways can overcome the high resistance to treatment and increase the selectivity of targeting malignant cells. This could effectively reduce the overall treatment-related toxicity and improve the general outcome.

Conclusions: Adhesion molecules facilitate growth of malignant diseases. This review provides a deeper insight into these processes. Modulation of adhesion molecules-mediated interactions is an innovative and feasible approach in treatment of AML and many other malignancies. Due to expected low toxicity it is an acceptable addition to standard chemotherapeutical regimens for all age groups of patients. This approach could improve the overall treatment outcome in the future.

Keywords: AML, adhesion molecules, prognosis, treatment approaches

Received: May 9, 2014; Accepted: September 16, 2014; Prepublished online: September 26, 2014; Published: March 9, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kupsa, T., Horacek, J.M., & Jebavy, L. (2015). The role of adhesion molecules in acute myeloid leukemia and (hemato)oncology: A systematic review. Biomedical papers, 159(1), 001-011. doi: 10.5507/bp.2014.049
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Krejsek J. Imunitní systém jako informaèní soustava. In: Krejsek J, Kopecky O. Klinická imunologie. Nukleus HK, 2004, p. 41-52.
    2. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357(9255):539-45. Go to original source... Go to PubMed...
    3. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420(6917):860-7. Go to original source... Go to PubMed...
    4. Kupsa T, Horacek JM, Jebavy L. The role of cytokines in acute myeloid leukemia: a systematic review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2012;156(4):291-301. Go to original source... Go to PubMed...
    5. Sanchez-Correa B, Bergua JM, Campos C, Gayoso I, Arcos MJ, Bañas H, Morgado S, Casado JG, Solana R, Tarazona R. Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels. Cytokine 2013;61(3):885-91. Go to original source... Go to PubMed...
    6. Hatfield K, Øyan AM, Ersvaer E, Kalland KH, Lassalle P, Gjertsen BT, Bruserud Ø. Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators. Br J Hematol 2009;144(1):53-68. Go to original source...
    7. Lampugnani MG, Resnati M, Raiteri M, Pigott R, Pisacane A, Houen G, Ruco LP, Dejana E. A novel-endothelial specific membrane protein is a marker of cell-cell contacts. J Cell Biol 1992;118(6):1511-22. Go to original source... Go to PubMed...
    8. Gotsch U, Borges E, Bosse R, Böggemeyer E, Simon M, Mossmann H, Vestweber D. VE-cadherin antibody accelerates neutrophil recruitment in vivo. J Cell Sci 1997;110:583-8. Go to original source... Go to PubMed...
    9. Corada M, Mariotti M, Thurston G, Smith K, Kunkel R, Brockhaus M, Lampugnani MG, Martin-Padura I, Stoppacciaro A, Ruco L, McDonald DM, Ward PA, Dejana E. Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc Natl Acad Sci USA 1999;96(17):9815-20. Go to original source... Go to PubMed...
    10. Esser S, Lampugnani MG, Corada M, Dejana E, Risau W. Vascular endothelial growth factor induces VE-cadherine tyrosine phosphorylation in endothelial cells. J Cell Sci 1998;111:1853-65. Go to original source... Go to PubMed...
    11. Girgis EH, Mahoney JP, Rafaat KH, Soliman MR. Effect of thalidomide and arsenic trioxide on the release of tumor necrosis factor-α and vascular endothelial growth factor from the KG-1a human acute myelogenous leukemia cell line. Oncology letters 2010;1(4):663-7. Go to original source... Go to PubMed...
    12. de Bont ES, Fidler V, Meeuwsen T, Scherpen F, Hählen K, Kamps WA. Vascular Endothelial Growth Factor Secretion Is an Independent Prognostic Factor for Relapse-free Survival in Pediatric Acute Myeloid Leukemia Patients. Clin Cancer Res 2002;8(9):2856-61.
    13. Casalou C, Fragoso R, Nunes JFM, Dias S. VEGF/PLGF induces leukemia cell migration via P38/ERK1/2 kinase pathway, resulting in Rho GTPases activation and caveolae formation. Leukemia 2007;21(7):1590-4. Go to original source... Go to PubMed...
    14. Casalou C, Costa A, Carvalho T, Gomes AL, Zhu Z, Wu Y, Dias S. Cholesterol Regulates VEGFR-1 (FLT-1) Expression and Signaling in Acute Leukemia Cells. Mol Cancer Res 2011;9(2):215-24. Go to original source... Go to PubMed...
    15. Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, Wu Y, Chadburn A, Hyjek E, Gill M, Hicklin DJ, Witte L, Moore MA, Rafii S. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000;106(4):511-21. Go to original source... Go to PubMed...
    16. Golay J, Cuppini L, Leoni F, Micò C, Barbui V, Domenghini M, Lombardi L, Neri A, Barbui AM, Salvi A, Pozzi P, Porro G, Pagani P, Fossati G, Mascagni P, Introna M, Rambaldi A. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia 2007;21(9):1892-900. Go to original source... Go to PubMed...
    17. Madlambayan GJ, Meacham AM, Hosaka K, Mir S, Jorgensen M, Scott EW, Siemann DW, Cogle CR. Leukemia regression by vascular disruption and antiangiogenic therapy. Blood 2010;116(9):1539-47. Go to original source... Go to PubMed...
    18. Morandini R, Ghanem G, Portier-Lemarié A, Robaye B, Renaud A, Boeynaems JM. Action of cAMP on expression and release of adhesion molecules in human endothelial cells. Am J Physiol 1996;270(3):807-16. Go to original source... Go to PubMed...
    19. Aubé C, Bélanger SD, St-Pierre Y. Lymphoma cells contribute to the augmentation of plasma sL-selectins in the serum of lymphoma-bearing mice. Leuk Lymphoma 2010;51(1):125-31. Go to original source... Go to PubMed...
    20. Ley K. The role of selectins in inflammation and disease. Trends Mol Med 2003;9(6):263-8. Go to original source... Go to PubMed...
    21. Lowe JB. Glycan-dependent leukocyte adhesion and recruitment in inflammation. Curr Opin Cell Biol 2003;15(5):531-8. Go to original source... Go to PubMed...
    22. Gege C, Geyer A, Schmidt RR. Synthesis and molecular tumbling properties of sialyl Lewis X and derived neoglycolipids. Chemistry 2002;8(11):2454-63. Go to original source... Go to PubMed...
    23. Etzioni A, Frydman M, Pollack S, Avidor I, Phillips ML, Paulson JC, Gershoni-Baruch R. Recurrent Severe Infections Caused by a Novel Leukocyte Adhesion Deficiency. N Engl J Med 1992;327(25):1789-92. Go to original source... Go to PubMed...
    24. Sarangapani KK, Qian J, Chen W, Zarnitsyna VI, Mehta P, Yago T, McEver RP, Zhu C. Regulation of catch bonds by rate of force application. J Biol Chem 2011;286(37): 32749-61. Go to original source... Go to PubMed...
    25. Ohmori K, Takada A, Ohwaki I, Takahashi N, Furukawa Y, Maeda M, Kiso M, Hasegawa A, Kannagi M, Kannagi R. A distinct type of sialyl Lewis X antigen defined by a novel monoclonal antibody is selectively expressed on helper memory T cells. Blood 1993;82(9):2797-805. Go to original source...
    26. Austrup F, Vestweber D, Borges E, Löhning M, Bräuer R, Herz U, Renz H, Hallmann R, Scheffold A, Radbruch A, Hamann A. P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflammed tissues. Nature 1997;385(6611):81-3. Go to original source... Go to PubMed...
    27. Nakayama F, Nishihara S, Iwasaki H, Kudo T, Okubo R, Kaneko M, Nakamura M, Karube M, Sasaki K, Narimatsu H. CD15 expression in mature granulocytes is determined by alpha 1,3-fucosyltransferase IX, but in promyelocytes and monocytes by alpha 1,3-fucosyltransferase IV. J Biol Chem 2001;276(19):16100-6. Go to original source... Go to PubMed...
    28. Yakubenia S, Wild MK. Leukocyte adhesion deficiency II. Advances and open questions. FEBS J 2006;273(19):4390-8. Go to original source... Go to PubMed...
    29. Fuster MM, Brown JR, Wang L, Esko JD. A disaccharide precursor of sialyl Lewis X inhibits metastatic potential of tumor cells. Cancer Res 2003;63(11):2775-81.
    30. Fuhlbrigge RC, Kieffer JD, Armerding D, Kupper TS. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature 1997;389(6654):978-81. Go to original source... Go to PubMed...
    31. Dimitroff CJ, Bernacki RJ, Sackstein R. Glycosylation-dependent inhibition of cutaneous lymphocyte-associated antigen expression: implications in modulating lymphocyte migration to skin. Blood 2003;101(2):602-10. Go to original source... Go to PubMed...
    32. Fuhlbrigge RC, King SL, Dimitroff CJ, Kupper TS, Sackstein R: Direct real-time observation of E- and P-selectin-mediated rolling on cutaneous lymphocyte-associated antigen immobilized on Western blots. J Immunol 2002;168(11):5645-51. Go to original source... Go to PubMed...
    33. Sackstein R. The bone marrow is akin to skin: HCELL and the biology of hematopoietic stem cell homing. J Invest Dermatol 2004;122(5):1061-9. Go to original source... Go to PubMed...
    34. Sackstein R, Merzaban JS, Cain DW, Dagia NM, Spencer JA, Lin CP, Wohlgemuth R. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med 2008;14(2):181-7. Go to original source... Go to PubMed...
    35. Gadhoum SZ, Sackstein R. CD15 expression in human myeloid cell differentiation is regulated by sialidase activity. Nat Chem Biol 2008;4(12):751-7. Go to original source... Go to PubMed...
    36. Fuhlbrigge RC, King SL, Sackstein R, Kupper TS. CD43 is a ligand for E-selectin on CLA+ human T cells. Blood 2006;107(4):1421-6. Go to original source... Go to PubMed...
    37. Nagy B, Szendroi A, Romics I. Overexpression of CD24, c-myc and phospholipase 2A in prostate cancer tissue samples obtained by needle biopsy. Pathol Oncol Res 2009;15(2):279-83. Go to original source... Go to PubMed...
    38. Kim KH, Choi JS, Kim JM, Choi YL, Shin YK, Lee HC, Seong IO, Kim BK, Chae SW, Kim SH. Enhanced CD24 expression in endometrial carcinoma and its expression pattern in normal and hyperplastic endometrium. Histol Histopathol 2009;24(3):309-16. Go to PubMed...
    39. Baumhoer D, Riener MO, Zlobec I, Tornillo L, Vogetseder A, Kristiansen G, Dietmar W, Hartmann A, Wuensch PH, Sessa F, Ruemmele P, Terracciano LM. Expression of CD24, P-cadherin and S100A4 in tumors of the ampulla of Vater. Mod Pathol 2009;22(2):306-13. Go to original source... Go to PubMed...
    40. Sano A, Kato H, Sakurai S, Sakai M, Tanaka N, Inose T, Saito K, Sohda M, Nakajima M, Nakajima T, Kuwano H. CD24 expression is a novel prognostic factor in esophageal squamous cell carcinoma. Ann Surg Oncol 2009;16(2):506-14. Go to original source... Go to PubMed...
    41. Yang XR, Xu Y, Yu B, Zhou J, Li JC, Qiu SJ, Shi YM, Wang XY, Dai Z, Shi GM, Wu B, Wu LM, Yang GH, Zhang BH, Qin WX, Fan J. CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery. Clin Cancer Res 2009;15(17):5518-27. Go to original source... Go to PubMed...
    42. Athanassiadou P, Grapsa D, Gonidi M, Athanassiadou AM, Tsipis A, Patsouris E. CD24 expression has a prognostic impact in breast carcinoma. Pathol Res Pract 2009;205(8):524-33. Go to original source... Go to PubMed...
    43. Wang W, Wang X, Peng L, Deng Q, Liang Y, Qing H, Jiang B. CD24-dependent MAPK pathway activation is required for colorectal cancer cell proliferation. Cancer Sci 2010;101(1):112-9. Go to original source... Go to PubMed...
    44. Rice GE, Bevilacqua MP. An inducible endothelial cell surface glycoprotein mediates melanoma adhesion. Science 1989;246(4935):1303-6. Go to original source... Go to PubMed...
    45. Stone JP, Wagner DD. P-selectin mediates adhesion of platelets to neuroblastoma and small cell lung cancer. J Clin Invest 1993;92(2):804-13. Go to original source... Go to PubMed...
    46. Kim YJ, Borsig L, Varki NM, Varki A. P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci USA 1998;95(16):9325-30. Go to original source... Go to PubMed...
    47. Borsig L, Wong R, Hynes RO, Varki NM, Varki A. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci USA 2001;99(4)3352-57. Go to original source...
    48. Takahashi S, Oda T, Hasebe T, Sasaki S, Kinoshita T, Konishi M, Ueda T, Nakahashi C, Ochiai T, Ochiai A. Overexpression of sialyl Lewis x antigen is associated with formation of extratumoral venous invasion and predicts postoperative development of massive hepatic metastasis in cases with pancreatic ductal adenocarcinoma. Pathobiology 2001;69(3):127-35. Go to original source... Go to PubMed...
    49. Ogawa J, Sano A, Koide S, Shohtsu A. Relation between recurrence and expression of proliferating cell nuclear antigen, sialyl Lewis(X), and sialyl Lewis(a) in lung cancer. J Thorac Cardiovasc Surg 1994;108(2):329-36. Go to original source...
    50. Nakamori S, Kameyama M, Imaoka S, Furukawa H, Ishikawa O, Sasaki Y, Izumi Y, Irimura T. Involvement of carbohydrate antigen sialyl Lewis(x) in colorectal cancer metastasis. Dis Colon Rectum 1997;40(4):420-31. Go to original source... Go to PubMed...
    51. Baldus SE, Mönig SP, Hanisch FG, Zirbes TK, Flucke U, Oelert S, Zilkens G, Madejczik B, Thiele J, Schneider PM, Hölscher AH, Dienes HP. Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl-Lewis(a) and sialyl-Lewis(x) antigens in colorectal adenocarcinoma. Histopathology 2002;40(5):440-9. Go to original source... Go to PubMed...
    52. Noguchi M, Sato N, Sugimori H, Mori K, Oshimi K. A minor E-selectin ligand, CD65, is critical for extravascular infiltration of acute myeloid leukemia cells. Leuk Res 2001;25(10):847-53. Go to original source... Go to PubMed...
    53. Fusté B, Mazzara R, Escolar G, Merino A, Ordinas A, Díaz-Ricart M. Granulocyte colony-stimulating factor increases expression of adhesion receptors on endothelial cells through activation of p38 MAPK. Haematologica 2004;89(5):578-85. Go to PubMed...
    54. Yamaguchi T, Ohshima K, Tsuchiya T, Suehuji H, Karube K, Nakayama J, Suzumiya J, Yoshino T, Kikuchi M. The comparison of expression of cutaneous lymphocyte-associated antigen (CLA), and Th1- and Th2-associated antigens in mycosis fungoides and cutaneous lesions of adult T cell leukemia/lymphoma. Eur J Dermatol 2003;13(6):553-9.
    55. Descheny L, Gainers ME, Walcheck B, Dimitroff CJ. Ameliorating skin-homing receptors on malignant T Cells with a fluorosugar analog of N-acetylglucosamine: P-selectin ligand is a more sensitive target than E-selectin ligand. J Invest Dermatol 2006;126(9): 2065-73. Go to original source... Go to PubMed...
    56. Dimitroff CJ, Lee JY, Rafii S, Fuhlbrigge RC, Sackstein R. Cd44 Is a Major E-Selectin Ligand on Human Hematopoietic Progenitor Cells. J Cell Biol 2001;153(6):1277-86. Go to original source... Go to PubMed...
    57. Greenberg AW, Kerr W, Hammer DA. Relationship between selectin-mediated rolling of hematopoietic stem and progenitor cells and progression in hematopoietic development. Blood 2000;95(2):478-86. Go to original source...
    58. Mazo IB, Gutierrez-Ramos JC, Frenette PS, Hynes RO, Wagner DD, von Andrian UH. Hematopoietic progenitor cell rolling in bone marrow microvessels: parallel contributions by endothelial selectins and vascular cell adhesion molecule 1. J Exp Med 1998;188(3):465-74. Go to original source... Go to PubMed...
    59. Katayama Y, Hidalgo A, Furie BC, Vestweber D, Furie B, Frenette PS. PSGL-1 participates in E-selectin-mediated progenitor homing to bone marrow: evidence for cooperation between E-selectin ligands and alpha4 integrin. Blood 2003;102(6):2060-7. Go to original source... Go to PubMed...
    60. Dagia NM, Gadhoum SZ, Knoblauch CA, Spencer JA, Zamiri P, Lin CP, Sackstein R. G-CSF induces E-selectin ligand expression on human myeloid cells. Nat Med 2006;12(10):1185-90. Go to original source... Go to PubMed...
    61. Winkler IG, Snapp KR, Simmons PJ, Lévesque JP. Adhesion to E-selectin promotes growth inhibition and apoptosis of human and murine hematopoietic progenitor cells independent of PSGL-1. Blood 2004;103(5):1685-92. Go to original source... Go to PubMed...
    62. Pezeshkian B, Donnelly C, Tamburo K, Geddes T, Madlambayan GJ. Leukemia Mediated Endothelial Cell Activation Modulates Leukemia Cell Susceptibility to Chemotherapy through a positive Feedback Loop Mechanism. Plos One 2013; 8(4):e60823. doi:10.1371/journal.pone.0060823 Go to original source... Go to PubMed...
    63. Nozawa F, Hirota M, Okabe A, Shibata M, Iwamura T, Haga Y, Ogawa M. Tumor necrosis factor alpha acts on cultured human vascular endothelial cells to increase the adhesion of pancreatic cancer cells. Pancreas 2000;21(4):392-8. Go to original source... Go to PubMed...
    64. Tanigawa N, Hagiwara M, Tada H, Komatsu T, Sugiura S, Kobayashi K, Kato Y, Ishida N, Nishida K, Ninomiya M, Koketsu M, Matsushita K. Acacetin inhibits expression of E-selectin on endothelial cells through regulation of the MAP kinase signaling pathway and activation of NF-κB. Immunopharmacol Immunotoxicol 2013;35(4):471-7. Go to original source... Go to PubMed...
    65. Mathieu S, Prorok M, Benoliel AM, Uch R, Langlet C, Bongrand P, Gerolami R, El-Battari A. Transgene expression of α(1,2)-fucosyltransferase-I (FUT1) in tumor cells selectively inhibits sialyl-Lewis x expression and binding to E-selectin without affecting synthesis of sialyl-Lewis a or binding to P-selectin. Am J Pathol 2004;164(2):371-83. Go to original source... Go to PubMed...
    66. Berlin C, Berg EL, Briskin MJ, Andrew DP, Kilshaw PJ, Holzmann B, Weissman IL, Hamann A, Butcher EC. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 1993;74(1):185-95. Go to original source... Go to PubMed...
    67. Arbonés ML, Ord DC, Ley K, Ratech H, Maynard-Curry C, Otten G, Capon DJ, Tedder TF. Lymphocyte homing and leukocyte rolling and migration are impaired in L-selectin-deficient mice. Immunity 1994:1(4):247-60. Go to original source... Go to PubMed...
    68. Katayama Y, Hidalgo A, Peired A, Frenette PS. Integrin alpha4beta7 and its counterreceptor MAdCAM-1 contribute to hematopoietic progenitor recruitment into bone marrow following transplantation. Blood 2004;104(7):2020-6. Go to original source... Go to PubMed...
    69. Hemmerich S, Bistrup A, Singer MS, van Zante A, Lee JK, Tsay D, Peters M, Carminati JL, Brennan TJ, Carver-Moore K, Leviten M, Fuentes ME, Ruddle NH, Rosen SD. Sulfation of L-selectin ligands by an HEV-restricted sulfotransferase regulates lymphocyte homing to lymph nodes. Immunity 2001;15(2):237-47. Go to original source... Go to PubMed...
    70. Hernandez Mir G, Helin J, Skarp KP, Cummings RD, Mäkitie A, Renkonen R, Leppänen A. Glycoforms of human endothelial CD34 that bind L-selectin carry sulfated sialyl Lewis x capped O- and N-glycans. Blood 2009;114(3):733-41. Go to original source... Go to PubMed...
    71. Rivera-Nieves J, Olson T, Bamias G, Bruce A, Solga M, Knight RF, Hoang S, Cominelli F, Ley K. L-Selectin, alpha 4 beta1, and alpha 4 beta 7 integrins participate in CD4+ T cell recruitment to chronically inflamed small intestine. J Immunol 2005;174(4):2343-52. Go to original source... Go to PubMed...
    72. von Andrian UH, Mempel TR. Homing and cellular traffic in lymph nodes. Nat Rev Immunol 2003;3(11):867-78. Go to original source... Go to PubMed...
    73. Bélanger SD, St-Pierre Y. Role of selectins in the triggering, growth, and dissemination of T-lymphoma cells: implication of L-selectin in the growth of thymic lymphoma. Blood 2005;105(12):4800-6. Go to original source... Go to PubMed...
    74. Ding Z, Issekutz TB, Downey GP, Waddell TK. L-selectin stimulation enhances fuctional expression of surface CXCR4 in lymphocytes: implications for cellular activation during adhesion and migration. Blood 2003;101(11):4245-52. Go to original source... Go to PubMed...
    75. Graf M, Reif S, Hecht K, Pelka-Fleischer R, Pfister K, Nuessler V, Schmetzer H. Low L-selectin (CD62L) expression in acute myeloid leukemia correlates with a bad cytogenetic risk. Eur J Hematol 2003;71(5):366-76. Go to original source... Go to PubMed...
    76. Aref S, Salama O, Al-Tonbary Y, Fouda M, Menessy A, El-Sherbiny M. L and E selectins in acute myeloid leukemia: expression, clinical relevance and relation to patient outcome. Hematology 2002;7(2):83-7. Go to original source... Go to PubMed...
    77. McEver RP, Beckstead JH, Moore KL, Marshall-Carlson L, Bainton DF. GMP-140, a platelet alpha-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. J Clin Invest 1989;84(1):92-99. Go to original source... Go to PubMed...
    78. Kaur J, Woodman RC, Kubes P. P38 MAPK: critical molecule in thrombin-induced NF-kappaB-dependent leukocyte recruitment. Am J Physiol Heart Circ Physiol 2003;284(4):H1095-103. Go to original source... Go to PubMed...
    79. Ley K, Bullard DC, Arbonés ML, Bosse R, Vestweber D, Tedder TF, Beaudet AL. Sequential contribution of L- and P-selectin to leukocyte rolling in vivo. J Exp Med 1995;181(2):669-75. Go to original source... Go to PubMed...
    80. Yao L, Pan J, Setiadi H, Patel KD, McEver RP. Interleukin 4 or oncostatin M induces a prolonged increase in P-selectin mRNA and protein in human endothelial cells. J Exp Med 1996;184(1):81-92. Go to original source... Go to PubMed...
    81. Tanaka M, Miyajima A. Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol 2003;149: 39-52. Go to original source... Go to PubMed...
    82. Somers WS, Tang J, Shaw GD, Camphausen RT. Insights into the molecular basis of leukocyte tethering and rolling revealed by structures of P- and E-selectin bound to SLe(X) and PSGL-1. Cell 2000;103(3):467-79. Go to original source... Go to PubMed...
    83. Martinez M, Joffraud M, Giraud S, Baïsse B, Bernimoulin MP, Schapira M, Spertini O. Regulation of PSGL-1 interactions with L-selectin, P-selectin, and E-selectin: role of human fucosyltransferase-IV and -VII. J Biol Chem 2005;280(7):5378-90. Go to original source... Go to PubMed...
    84. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002;110(6):673-87. Go to original source... Go to PubMed...
    85. Lee BH, Ruoslahti E. Alpha5beta1 integrin stimulates Bcl-2 expression and cell survival through Akt, focal adhesion kinase, and Ca2+/calmodulin-dependent protein kinase IV. J Cell Biochem 2005;95(6):1214-23. Go to original source... Go to PubMed...
    86. Rothlein R, Dustin ML, Marlin SD, Springer TA. A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J Immunol 1986;137(4):1270-4. Go to original source...
    87. Merzaban JS, Burdick MM, Gadhoum SZ, Dagia NM, Chu JT, Fuhlbrigge RC, Sackstein R. Analysis of glycoprotein E-selectin ligands on human and mouse marrow cells enriched for hematopoietic stem/progenitor cells. Blood 2011;118(7):1774-83. Go to original source... Go to PubMed...
    88. Etzioni A, Doershuk CM, Harlan JM. Of man and mouse: leukocyte and endothelial adhesion molecule deficiencies. Blood 1999;94(10):3281-8. Go to original source...
    89. Zarbock A, Ley K. Neutrophil adhesion and activation under flow. Microcirculation 2009;16(1):31-42. Go to original source... Go to PubMed...
    90. Cheng Q, McKeown SJ, Santos L, Santiago FS, Khachigian LM, Morand EF, Hickey MJ. Macrophage migration inhibitory factor increases leukocyte-endothelial interactions in human endothelial cells via promotion of expression of adhesion molecules. J Immunol 2010;185(2):1238-47. Go to original source... Go to PubMed...
    91. Burger JA, Spoo A, Dwenger A, Burger M, Behringer D. CXCR4 chemokine receptors (CD184) and alpha4beta1 integrins mediate spontaneous migration of human CD34+ progenitors and acute myeloid leukaemia cells beneath marrow stromal cells (pseudoemperipolesis). Br J Haematol 2003;122(4):579-89. Go to original source... Go to PubMed...
    92. Matsunaga T, Takemoto N, Sato T, Takimoto R, Tanaka I, Fujimi A, Akiyama T, Kuroda H, Kawano Y, Kobune M, Kato J, Hirayama Y, Sakamaki S, Kohda K, Miyake K, Niitsu Y. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003;9(9):1158-65. Go to original source... Go to PubMed...
    93. De Toni F, Racaud-Sultan C, Chicanne G, Mas VM, Cariven C, Mesange F, Salles JP, Demur C, Allouche M, Payrastre B, Manenti S, Ysebaert L. A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia. Oncogene 2006;25(22):3113-22. Go to original source... Go to PubMed...
    94. Mraz M, Zent CS, Church AK, Jelinek DF, Wu X, Pospisilova S, Ansell SM, Novak AJ, Kay NE, Witzig TE, Nowakowski GS. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance. Br J Hematol 2011;155(1):53-64. Go to original source...
    95. Becker PS, Kopecky KJ, Wilks AN, Chien S, Harlan JM, Willman CL, Petersdorf SH, Stirewalt DL, Papayannopoulou T, Appelbaum FR. Very late antigen-4 function of myeloblasts correlates with improved overal survival for patients with acute myeloid leukemia. Blood 2009;113(4):866-74. Go to original source... Go to PubMed...
    96. Walter RB, Alonzo TA, Gerbing RB, Ho PA, Smith FO, Raimondi SC, Hirsch BA, Gamis AS, Franklin JL, Hurwitz CA, Loken MR, Meshinchi S. High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group. J Clin Oncol 2010;28(17):2831-8. Go to original source... Go to PubMed...
    97. Shalapour S, Hof J, Kirschner-Schwabe R, Bastian L, Eckert C, Prada J, Henze G, von Stackelberg A, Seeger K. High VLA-4 expression is associated with adverse outcome and distinct gene expression changes in childhood B-cell precursor acute lymphoblastic leukemia at relapse. Haematologica 2011;96(11):1627-35. Go to original source... Go to PubMed...
    98. Soede RD, Wijnands YM, Van Kouteren-Cobzaru I, Roos E. ZAP-70 tyrosine kinase is required for LFA-1-dependent T cell migration. J Cell Biol 1998;142(5):1371-9. Go to original source... Go to PubMed...
    99. Aoudjit F, Potworowski EF, Springer TA, St-Pierre Y. Protection from lymphoma cell metastasis in ICAM-1 mutant mice: a posthoming event. J Immunol 1998;161(5):2333-8. Go to original source...
    100. Bella J, Kolatkar PR, Marlor CW, Greve JM, Rossmann MG. The structure of the two amino-terminal domains of human ICAM-1 suggests how it functions as a rhinovirus receptor and as an LFA-1 integrin ligand. Proc Natl Acad Sci USA 1998;95(8):4140-5. Go to original source... Go to PubMed...
    101. Holland J, Owens T. Signaling through intercellular adhesion molecule 1 (ICAM-1) in a B cell lymphoma line. The activation of Lyn tyrosine kinase and the mitogen-activated protein kinase pathway. J Biol Chem 1997;272(14):9108-12. Go to original source... Go to PubMed...
    102. Etienne-Manneville S, Chaverot N, Strosberg AD, Couraud PO. ICAM-1-coupled signaling pathways in astrocytes converge to cyclic AMP response element-binding protein phosphorylation and TNF-alpha secretion. J Immunol 1999;163(2):668-74. Go to original source...
    103. Scaldaferri F, Sans M, Vetrano S, Correale C, Arena V, Pagano N, Rando G, Romeo F, Potenza AE, Repici A, Malesci A, Danese S. The role of MAPK in governing lymphocyte adhesion to and migration across the microvasculature in inflammatory bowel disease. Eur J Immunol 2009;39(1):290-300. Go to original source... Go to PubMed...
    104. Blaber R, Stylianou E, Clayton A, Steadman R. Selective regulation of ICAM-1 and RANTES gene expression after ICAM-1 ligation on human renal fibroblasts. J Am Soc Nephrol 2003;14(1):116-27. Go to original source... Go to PubMed...
    105. Barreiro O, Yanez-Mo M, Serrador JM, Montoya MC, Vicente-Manzanares M, Tejedor R, Furthmayr H, Sanchez-Madrid F. Dynamic interaction of VCAM-1 and ICAM-1 with moesin and ezrin in a novel endothelial docking structure for adherent leukocytes. J Cell Biol 2002;157(7):1233-45. Go to original source... Go to PubMed...
    106. Fritz DK, Kerr C, Tong L, Smyth D, Richards CD. Oncostatin-M up-regulates VCAM-1 and synergizes with IL-4 in eotaxin expression: involvement of STAT6. J Immunol 2006;176(7):4352-60. Go to original source... Go to PubMed...
    107. Fukuda K, Nishida T, Fukushima A. Synergistic induction of eotaxin and VCAM-1 expression in human corneal fibroblasts by staphylococcal peptidoglycan and either IL-4 or IL-13. Allergol Int 2011;60(3):355-63. Go to original source... Go to PubMed...
    108. Stucki A, Rivier AS, Gikic M, Monai N, Schapira M, Spertini O. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood 2001;97(7):2121-9. Go to original source... Go to PubMed...
    109. Parmo-Cabañas M, Bartolome RA, Wright N, Hidalgo A, Drager AM, Teixidó J. Integrin alpha4beta1 involvement in stromal cell-derived factor-1alpha-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion. Exp Cell Res 2004;294(2):571-80. Go to original source... Go to PubMed...
    110. Kucia M, Reca R, Miekus K, Wanzeck J, Wojakowski W, Janowska-Wieczorek A, Ratajczak J, Ratajczak MZ. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 2005;23(7):879-94. Go to original source... Go to PubMed...
    111. Ngo HT, Leleu X, Lee J, Jia X, Melhem M, Runnels J, Moreau AS, Burwick N, Azab AK, Roccaro A, Azab F, Sacco A, Farag M, Sackstein R, Ghobrial IM. SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. Blood 2008;112(1):150-8. Go to original source... Go to PubMed...
    112. Konoplev S, Rassidakis GZ, Estey E, Kantarjian H, Liakou CI, Huang X, Xiao L, Andreeff M, Konopleva M, Medeiros LJ. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer 2007;109(6):1152-6. Go to original source... Go to PubMed...
    113. Spoo AC, Lübbert M, Wierda WG, Burger JA. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood 2007;109(2)786-91. Go to original source... Go to PubMed...
    114. Mannelli F, Cutini I, Gianfaldoni G, Bencini S, Scappini B, Pancani F, Ponziani V, Bonetti MI, Biagiotti C, Longo G, Bosi A. CXCR4 expression accounts for clinical phenotype and outcome in acute myeloid leukemia. Cytometry B Clin Cytom 2014;86(5):340-9. Go to original source... Go to PubMed...
    115. Hazlehurst LA, Valkov N, Wisner L, Storey JA, Boulware D, Sullivan DM, Dalton WS. Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood 2001;98(6):1897-903. Go to original source... Go to PubMed...
    116. Macanas-Pirard P, Leisewitz A, Broekhuizen R, Cautivo K, Barriga FM, Leisewitz F, Gidi V, Riquelme E, Montecinos VP, Swett P, Besa P, Ramirez P, Ocqueteau M, Kalergis AM, Holt M, Rettig M, DiPersio JF, Nervi B. Bone marrow stromal cells modulate mouse ENT1 activity and protect leukemia cells from cytarabine induced apoptosis. PLoS One 2012;7(5):e37203. doi: 10.1371/journal.pone.0037203. Go to original source... Go to PubMed...
    117. Tavor S, Petit I, Porozov S, Avigdor A, Dar A, Leider-Trejo L, Shemtov N, Deutsch V, Naparstek E, Nagler A, Lapidot T. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res 2004;64(8):2817-24. Go to original source... Go to PubMed...
    118. Owens LV, Xu L, Craven RJ, Dent GA, Weiner TM, Kornberg L, Liu ET, Cance WG. Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res 1995;55(13):2752-5. Go to PubMed...
    119. Tavernier-Tardy E, Cornillon J, Campos L, Flandrin P, Duval A, Nadal N, Guyolat D. Prognostic value of CXCR4 and FAK expression in acute myelogenous leukemia. Leukemia Research 2009;33(6):764-8. Go to original source... Go to PubMed...
    120. Mandawat A, Fiskus W, Buckley KM, Robbins K, Rao R, Balusu R, Navenot JM, Wang ZX, Ustun C, Chong DG, Atadja P, Fujii N, Peiper SC, Bhalla K. Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists. Blood 2010;116(24):5306-15. Go to original source... Go to PubMed...
    121. Beider K, Begin M, Abraham M, Wald H, Weiss ID, Wald O, Pikarsky E, Zeira E, Eizenberg O, Galun E, Hardan I, Engelhard D, Nagler A, Peled A. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Exp Hematology 2011;39(3):282-92. Go to original source...
    122. Flomenberg N, Devine SM, DiPersio JF, Liesveld J, McCarty JM, Rowley SD, Vesole DH, Badel K, Calandra G. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005;106(5):1867-74. Go to original source... Go to PubMed...
    123. Zeng Z, Samudio IJ, Munsell M, An J, Huang Z, Estey E, Andreeff M, Konopleva M. Inhibition of CXCR4 with the novel RCP 168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancor Ther 2006;5(12):3113-21. Go to original source...
    124. Rombouts EJ, Pavic B, Löwenberg B, Ploemacher RE. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 2004;104(2):550-7. Go to original source... Go to PubMed...
    125. Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O, Levis M, Rubin JB, Negrin RR, Estey EH, Konoplev S, Andreeff M, Konopleva M. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistence to kinase inhibitors and chemotherapy in AML. Blood 2009;113(24):6215-24. Go to original source... Go to PubMed...
    126. Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM, Kulkarni S, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Vij R, Westervelt P, DiPersio JF. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 2012;119(17):3917-24. Go to original source... Go to PubMed...
    127. Sison EA, McIntyre E, Magoon D, Brown P. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistence in pediatric AML. Mol Cancer Res 2013;11(9);1004-16. Go to original source... Go to PubMed...
    128. Niedermeier M, Hennessy BT, Knight ZA, Henneberg M, Hu J, Kurtova AV, Wierda WG, Keating MJ, Shokat KM, Burger JA. Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 2009;113(22):5549-57. Go to original source... Go to PubMed...
    129. Brault L, Rovó A, Decker S, Dierks C, Tzankov A, Schwaller J. CXCR4-SERINE339 regulates cellular adhesion, retention and mobilization, and is a marker for poor prognosis in acute myeloid leukemia. Leukemia 2014;28(3):566-76. Go to original source... Go to PubMed...
    130. Grundler R, Brault L, Gasser C, Bullock AN, Dechow T, Woetzel S, Pogacic V, Villa A, Ehret S, Berridge G, Spoo A, Dierks C, Biondi A, Knapp S, Duyster J, Schwaller J. Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. J Exp Med 2009;206(9):1957-70. Go to original source... Go to PubMed...
    131. Decker S, Finter J, Forde A, Kissel S, Schwaller J, Mack TS, Kuhn A, Gray NS, Follo M, Jumaa H, Burger M, Zirlik K, Pfeifer D, Miduturu C, Eibel H, Veelken H, Dierks C. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4 mediated microenvironmental interactions (PIM1). Mol Cancer Ther 2014;13(5):1231-45. Go to original source... Go to PubMed...
    132. Alves CS, Yakovlev S, Medved L, Konstantopoulos K. Biomolecular characterization of CD44-fibrin(ogen) binding: distinct molecular requirements mediate binding of standard and variant isoforms of CD44 to immobilized fibrin(ogen). J Biol Chem 2009;284(2):1177-89. Go to original source... Go to PubMed...
    133. Sackstein R, Dimitroff CJ. A hematopoietic cell L-selectin ligand that is distinct from PSGL-1 and displays N-glycan-dependent binding activity. Blood 2000;96(8):2765-74. Go to original source...
    134. Thankamony SP, Sackstein R. Enforced hematopoietic cell E- and L-selectin ligand (HCELL) expression primes transendothelial migration of human mesenchymal stem cells. Proc Natl Acad Sci USA 2011;108(6):2258-63. Go to original source... Go to PubMed...
    135. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006;12(10):1167-74. Go to original source... Go to PubMed...
    136. Zhang S, Wu CC, Fecteau JF, Cui B, Chen L, Zhang L, Wu R, Rassenti L, Lao F, Weigand S, Kipps TJ. Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proc Natl Acad Sci USA 2013;110(15):6127-32. Go to original source... Go to PubMed...
    137. Burdick MM, Chu JT, Godar S, Sackstein R. HCELL is the major E- and L-selectin ligand expressed on LS174T colon carcinoma cells. J Biol Chem 2006;281(20):13899-905. Go to original source... Go to PubMed...
    138. Thomas SN, Zhu F, Schnaar RL, Alves CS, Konstantopoulos K. Carcinoembryonic antigen and CD44 variant isoforms cooperate to mediate colon carcinoma cell adhesion to E- and L-selectin in shear flow. J Biol Chem 2008;283(23):15647-55. Go to original source... Go to PubMed...
    139. Al-Souhibani N, Al-Ghamdi M, Al-Ahmadi W, Khabar KS. Post-transcriptional control of the chemokine receptor CXCR4 expression in cancer cells. Carcinogenesis 2014;35(9):1983-92. Go to original source... Go to PubMed...
    140. Li F, Tiede B, Massagué J, Kang Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res 2007;17(1):3-14. Go to original source... Go to PubMed...
    141. Yan W, Chen Y, Yao Y, Zhang H, Wang T. Increased invasion and tumorigenicity capacity of CD44+/CD24- breast cancer MCF7 cells in vitro and in nude mice. Cancer Cell Int 2013;13(1):62. Go to original source... Go to PubMed...
    142. Ni J, Cozzi PJ, Hao JL, Beretov J, Chang L, Duan W, Shigdar S, Delprado WJ, Graham PH, Bucci J, Kearsley JH, Li Y. CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance. Prostate 2014;74(6):602-17. Go to original source... Go to PubMed...
    143. Wang SJ, Wong G, de Heer AM, Xia W, Bourguignon LY. CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope 2009;119(8):1518-30. Go to original source... Go to PubMed...
    144. Sillanpää S, Anttila MA, Voutilainen K, Tammi RH, Tammi MI, Saarikoski SV, Kosma VM. CD44 expression indicates favorable prognosis in epithelial ovarian cancer. Clin Cancer Res 2003;9(14):5318-24.
    145. Sackstein R. Glycosyltransferase-programmed stereosubstitution (GPS) to create HCELL: engineering a roadmap for cell migration. Immunol Rev 2009;230(1):51-74. Go to original source... Go to PubMed...
    146. Sackstein R. Engineering cellular trafficking via glycosyltransferase-programmed stereosubstitution. Ann NY Acad Sci 2012;1253(1):193-200. Go to original source... Go to PubMed...
    147. Jacobs PP, Sackstein R. CD44 and HCELL: Preventing Hematogenous metastasis at step 1. FEBS Lett 2011;585(20):3148-58. Go to original source... Go to PubMed...

    Return to the content